Sidley represented Yuhan Corporation in its joint development and licensing agreement with Boehringer Ingelheim, for the development of dual agonist innovative drugs with the activity of GLP-1 and FGF21 to treat nonalcoholic steatohepatitis (NASH) and related liver disease. Under this agreement, Yuhan will receive US$40 million as a down payment, and up to US$830 million in milestone payments and additional royalties on net sales in the future.
Through the joint development, the two companies expect to create synergy by combining Boehringer Ingelheim’s expertise and dedication to provide innovative medicines to patients with cardiovascular, metabolic disorders and Yuhan’s expertise in FGF21, obesity and NASH. It is the first export of a South Korea-developed biopharmaceutical technology to treat NASH.
The deal was led by partner Josh Hofheimer (Los Angeles) with counsel Lauren Grau (Dallas).
“Josh and Lauren have represented Yuhan Corporation in a series of major licensing deals including the latest one with Boehringer Ingelheim and every experience with them was of the highest caliber. Josh’s team has always been highly responsive to our tough demands. It is a pleasure to work with them.” says Jaekyo Kim, Executive Vice President heading the Global Strategy Department at Yuhan Corporation.